In a recent study using neuroblastoma and melanoma mouse models to evaluate the roles of CD200R signaling in tumor growth and immunity, it was reported (in accord with the EMT6 breast cancer model discussed above) that CD200RKO mice were significantly more potent in rejecting these CD200+ tumors [85]. This evidence concerns the gene CD200 and neoplasm.